We evaluated the analytical and clinical performance of an immunoassay for cardiac troponin T (cTnT). Within-run and total imprecision ranged from 1.6 to 11.3%. The sensitivity and linear range was 0.015 and 13 g/L, respectively. Frozen samples were stable for at least 8 weeks. No interferences were seen with lipids or bilirubin (total and conjugated). Hemoglobin caused a negative bias at concentrations >4 gIL. Heparinized plasma showed a 6% negative bias compared with serum. The clinical utilityof cTnT was compared with that of creatine kinase (CK)-MB (mass assay). The sensitivityof cTnT measurements from 63 patients with acute myocardial infarction (AMI) (cTnT cutoff 0.1 g/L) was 60% at 0-3 h, 59% at 3-6 h, 94% at 6-9 h, 90% at 9-12 h, 99% at 12-24 h, 92% at Ii, 83% at 48-72 h, and 100% at 72-96 h. Corresponding results for CK-MB (cutoff 5.0 pg/L and 2.5% relative index) were 45%, 64%, 82%, 97%, 87%, 81%, 54%, and 59%. The specificity of the markers from 49 non-AMI patients was 46% and 79% for cTnT and CK-MB, respectively. We show that CK-MB is more specificfor diagnosis of AMI, and propose that cTnT is more sensitive to myocardial injury. ! (7, 9, 10, 16 ). These studies either used earlier versions of the cTnT assay (9) or analyzer (ES22)(5, 10), or compared results with CK-MB by immunoinhibition (5, 9, 10).
The purpose of this multicenter study was to evaluate the analytical and clinical performance of the cThT assay on the ES 300 for imprecision, transferability, all from Beckton Dickinson (Rutherford, NJ). These tubes were used to assess the effects of anticoagulant interference in the assay; a 95% confidence (P <0.05) interval was used for comparing differences.
Reference range. We randomly selected and equally distributed 112 healthy ambulatory subjects from each hospital site for the reference range study. These subjects were deemed free of clinical complications or medications on the basis of interviews.
CK-MB in these samples was measured by immunoassay. The reference range for cThT was determined from the central 95% of values from this population. known to attending physicians and was not used in making the diagnosis. 
Many of these

Results
AnalyticalStudy
Assay calibration.
In Fig. 1 The recovery values for a blank serum sample supplemented with high cThT were 93%, 100%, and 101% for expected cThT concentrations of 3.84, 6.33, and 6.90 pg/L, respectively.
Stability of cTnT. In Fig. 2 Reference range. All normal subjects had CK-MB values that were within the reference range established at each institution. The results for cThT are shown in Fig.   4 and indicate a skewed distribution.
Using the central 95%, we calculated the reference range to be 0-0.08 jJL. This is within the cutoff limit of 0.10 pgfL recommended by the manufacturer for diagnosis of myocardial injury.
ClinicalStudy
Diagnostic efficiency for AMI. Table 2 shows the data for cThT and CK-MB for all the patients studied. For AM! patients, the data are further grouped according to the reported time of onset of chest pain. In Fig. 5 , ROC curves are presented that indicate the clinical sensitivity and specificity at different cutoff limits. 
DIscussIon
This study describes the first evaluation of a cTnT assay performed on the ES300 analyzer in the US. The imprecision studies for cTnT from three laboratories demonstrated
CVs that compare well with other reports (5, 10, 13, 16 ). Between sites, the day-to-day reproducibffity of controls gave consistent values with no drifts or shifts, demonstrating assay transferability. Interference studies showed that hemoglobin concentrations (>4 g/L) reduced the recovery of cTnT in serum by >10%. Although the mechanism was not studied, the interference may be related to the initial absorbance at 405 nm, with the reaction rate being influenced by nonspecific adherence and absorbance of hemoglobin or red cell constituents remaining after the washing procedure. In any event, slight to moderate hemolysis (hemoglobin <4 g/L) did not cause interference.
Bilirubin and lipids did not interfere with this assay. We believe that the discordance in our data was due to differences in the inclusion criteria for patients selected in our study as compared with others. We purposely included serum from critically ill patients and those with multisystem disorders.
We suggest that increased cTnT in some of these non-AM! patients was due to the existence of minor myocardial injuries not detected by CK-MB.
Other explanations for high cTnT in these patients were used (16). Also, cTnT may be upregulated after skeletal muscle injury. Although cTnT is absent in normal human skeletal muscles, cardiac and skeletal muscle forms are coexpressed during fetal development (24). Fetal cTnT isoforms that are normally absent in adult cardiac tissue are transiently expressed in adult patients with failing hearts (25). Moreover, fetal expression of cTnT has been demonstrated in regenerating skeletal muscle fibers of rats subjected to cold injury and denervation (26). However, there are no reports to date to suggest that cardiac expression of troponin T occurs after repair of skeletal muscle injury in humans.
The ROC curves (Fig. 5) show that cThT has a lower clinical specificity and diagnostic efficiency than CK-MB in the diagnosis of AM!. If the objective of the cTnT assay is diagnosis of AM!, our data suggest that CK-MB may be superior to cThT during the first 48 h. However, if detection of myocardial injury (to include AMI) is the objective, then cThT maybe more sensitive and specific than CK-MB. As shown in Fig. 8 , the cutoff concentration of CK-MB is set a few units above the upper reference The baseline concentration of CK-MB Is higher than for cTnT because the former contains a significant skeletalmuscle component. The cutoff concentrations for CK-MBmust be set relatively high(e.g.,5 Mg/I). cml hasvery little residual baseline concentration, and a relatively low cutoff concentration can be selected (e.g., 0.1 g/L), facilitating detection of minormyocardial Injury. limit so that patients with minor myocardial injury may have higher-than-normal CK-MB concentrations that are stifi below the cutoff. Some investigators have lowered CK-MB limits to detect minor myocardial injury (27, 28). However, the utility of CK-MB will ultimately be limited by the inability of the marker to distinguish myocardial injury from skeletal muscle damage. For cTnT, selecting a cutoff at the upper limit of normal (Fig. 8) could be useful for detecting minor myocardial injury because there is no cTnT contribution from skeletal muscles. A higher cTnT cutoff limit could be used to improve clinical specificity for AM! diagnosis; however, the detection of minor myocardial injury will be lost. Under this assumption, many patients with unstable angina will have injury detectable by increased concentrations of a sensitive and specific marker such as cTnT.
